Skip to main content
Figure 3 | Radiation Oncology

Figure 3

From: BAY 87–2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts

Figure 3

Effects of BAY-87-2243 on tumor microenvironment and tumor growth. a) Pimonidazole hypoxic fraction (pHF), relative vascular area (RVA), fraction of perfused vessels (PF), and necrotic fraction (NF) in UT-SCC-5 tumors 24 h after end of treatment with BAY-87-2243 or carrier for 3, 5, or 7 days (n=7-9 tumors per time point and treatment group). b) Time to grow from 4 to 7 mm tumor diameter. UT-SCC-5 tumors were treated daily with BAY-87-2243 or carrier. Bars represent means ± SD of histological parameters or medians ± MAD (median absolute deviation) of growth times. Asterisks indicate significant differences from carrier control.

Back to article page